Latest Posts:
Search for:
Author

Xin Tao

Browsing
In Healthcare Services

The U.S. Department of Health and Human Services  Issues Favorable Opinion on Healthcare Company’s Donations to Charitable Foundation

by and 5 Mins Read

In brief On September 11, 2025, the U.S. Department of Health and Human Services (“HHS”) Office of Inspector General (“OIG”) released a favorable advisory opinion (“AO 25-10”), addressing a financial arrangement between a healthcare services company (the “Company”) and a non-profit, tax-exempt, charitable foundation (the “Foundation”), pursuant to which the Company helped establish and makes donations to the Foundation and the Foundation provides financial assistance to families of children receiving a particular type of behavioral…

Read More
In Medical Devices

Healthcare & Life Sciences Supply Chains Series: Trade Winds, Tariffs, and Optimizing Operations (2 of 4)

by , , , , , , , and 1 Min Read

Amid fluctuating tariffs and complex trade policies, healthcare and life sciences (HLS) companies face mounting operational and legal challenges within their global supply chains. Organizations are taking steps to retool their supply chains in response to threats against stability, but change introduces myriad knock-on implications. In the second article of the series, we explore four key questions for HLS businesses considering new supply chain strategies:

Read More
In Pharmaceuticals & Biotech

New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing

by , , , , , , , , , and 7 Mins Read

On May 12, 2025, the White House issued a wide-reaching Executive Order (“EO”) titled “Delivering Most Favored Nation Prescription Drug Pricing to American Patients” for the stated purpose of ensuring that American patients will have access to the most-favored-nation (“MFN”) price for prescription drugs and biologics.1 This EO came out about one month after the release of EO No. 14273 titled “Lowering Drug Prices by Once Again Putting Americans First” (April 15, 2025) which outlined…

Read More
In Healthcare Services

Psychedelics – will reform happen fast enough?

by , and 4 Mins Read

The conversation on psychedelics around the world continues to evolve, with more and more emerging clinical data highlighting their potential to treat mental health disorders. Last year’s developments – see our previous blog post here – led us to anticipate an upcoming change but yet the legal landscape remains unchanged. In the UK, the independent Parliamentary Office of Science and Technology (POST), which is one of the first independent bodies of its kind in the…

Read More
In Pharmaceuticals & Biotech

The BIOSECURE Act: Potential Implications for Biotechnology Collaborations with Chinese Companies

by , , , , , and 1 Min Read

Bipartisan legislation advancing in the U.S. Senate and the U.S. House of Representatives known as the “BIOSECURE Act” (“the Act”) has the potential to restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the U.S. government. Following the same model that was used to target Chinese telecommunications companies in the late 2010s, the Act would prohibit federal “executive agencies” from contracting with or extending loans…

Read More
In Digital Health

Key Legal Trends in The United States For Healthcare And Life Sciences In 2024

by and 1 Min Read

In brief As we look back at 2023, we reflect on a year marked by significant developments in the legal framework governing the life sciences and healthcare industries in the US. These developments include the implementation of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act; the rise of artificial intelligence in drug development and manufacturing; the evolving landscape of US Food and Drug Administration regulation and enforcement of laboratory-developed tests; and the…

Read More
In Healthcare Services

The Tide is Turning for Psychedelics-based Therapies in the UK

by , and 6 Mins Read

Last month, the UK House of Commons debated the current state of regulatory and legal hurdles negatively affecting the development of psilocybin-based (the psychedelic compound most commonly found in ‘magic mushrooms’) therapies for mental and physical health disorders in the UK. The debate resulted from an e-petition, which garnered 11,824 votes in February this year. The debate saw a consensus among Members of Parliament across party lines, collectively supporting the proposal for rescheduling psilocybin from…

Read More